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Abstract
Background: Hydromorphone is a standard opioid analgesic for cancer pain that, prior to this
study, was not approved in Japan, where options for opioid switching are limited. We aimed to
investigate the efficacy and safety of hydromorphone (DS-7113b) immediate-release tablets in opi-
oid-naïve cancer patients with moderate to severe cancer pain.
Methods: Multicenter, active-controlled, randomized, double-blind, parallel-group, non-inferiority study
of 183 cancer patients over 20 years of age at 50 clinical sites in Japan. Hydromorphone tablets or oxy-
codone hydrochloride powder was orally administered four times daily for 5 days. The initial doses of
hydromorphone and oxycodone hydrochloride were 4mg/day and 10mg/day, respectively, and
adjusted as necessary. Efficacy was evaluated as the intergroup difference (95% confidence interval
[CI]) of the least squares mean by analysis of covariance, using the baseline visual analog scale (VAS)
as a covariate for change in VAS score at treatment completion/discontinuation in the full analysis set.
Results: Non-inferiority of hydromorphone versus oxycodone was confirmed, with an intergroup
difference (95% CI) in the least squares mean of −3.4mm (−9.8 to 3.1mm) for change in VAS
scores, which was below the upper limit of the 95% CI at 10mm, the non-inferiority limit deter-
mined during study planning. Adverse events occurred in 83.0% (73/88) of patients in the hydro-
morphone group and 77.4% (65/84) in the oxycodone group. The most frequently observed
adverse events were somnolence, constipation, vomiting and nausea.
Conclusions: The efficacy and safety of hydromorphone tablets are equivalent to those of oxy-
codone immediate-release powder.
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Introduction
Analgesia for cancer pain is based on the World Health Organization
Guidelines for cancer pain relief published in 1986 (1). The World
Health Organization’s ‘three-step ladder for cancer pain relief’ recom-
mends the use of analgesics depending on the severity of pain, and
the use of potent opioid analgesics is stipulated for moderate to severe
pain (1). Potent opioid analgesics are the most effective for relieving
cancer pain and can provide successful pain control (2). Morphine,
oxycodone and fentanyl are currently used in Japan as the Step 3 opi-
oid analgesics (3).
Hydromorphone is a selective μ-opioid receptor agonist analgesic
that was synthesized in Germany in the 1920s and is currently used
clinically in 45 countries and regions in the world (4). Hydromorphone
is an alternative drug for morphine (5–8), but at the time this study
commenced, it was not approved for use in Japan. Options for opioid
switching are limited in Japan, so a request for the development of
hydromorphone was submitted by the Japanese Society for Palliative
Medicine.
We conducted a Phase 3, randomized, double-blind, comparative
study to investigate the non-inferiority of hydromorphone tablets
relative to oxycodone hydrochloride powder, and to investigate the
efficacy of hydromorphone tablets in Japanese opioid-naïve patients
with cancer pain.
Patients and methods
This study was conducted from 2013 to 2014 as a multicenter,
active-controlled, randomized, double-blind, parallel-group com-
parison study, enrolling 183 patients at 50 sites. The participating
centers and institutes are listed in the Supplemental File. The study
was approved by the institutional review board of each study site
and was conducted in compliance with ethical principles based on
the Declaration of Helsinki and Good Clinical Practice. Written
informed consent was obtained from all patients prior to study
participation.
Participants
The study participants were cancer patients over 20 years of age
receiving non-opioid analgesics for pain relief who had not used opi-
oid analgesics within 2 weeks of registration. At registration, the
average pain within the last 24 h, as measured on the visual analog
scale (VAS), was required to be ≥35mm and Eastern Cooperative
Oncology Group (ECOG) performance status (PS) was required to
be ≤3. All patients were judged by the investigator to require treat-
ment with potent opioid analgesics. Exclusion criteria included
patients presenting with symptoms for which oxycodone or mor-
phine are contraindicated or relatively contraindicated, patients
receiving treatment with a monoamine oxidase inhibitor within 14
days of registration, patients participating in another clinical trial
within 28 days of registration, and patients with a serious hepatic,
renal or respiratory disorder of Common Terminology Criteria for
Adverse Events Grade 3.
Study design
Patients were randomly allocated 1:1 to either hydromorphone
immediate-release tablets (DS-7113b; Daiichi-Sankyo, Tokyo, Japan) or
oxycodone immediate-release powder (OxiNorm® Powder; Shionogi,
Osaka, Japan). The computer-generated block random allocation
sequence was provided by Bell Medical Solutions Inc. (Tokyo, Japan)
and was stratified according to history of opioid usage. A double-
dummy method was employed for blinding, and patients received either
hydromorphone plus placebo or a placebo tablet plus oxycodone
hydrochloride powder orally four times daily for 5 days. This dosage
frequency was selected based on the standard pharmacokinetic profile
for immediate-release hydromorphone (i.e., onset of action in ~30min
and duration of action ~4 h) (9). The initial doses of hydromorphone
and oxycodone hydrochloride were 4mg/day and 10mg/day, respect-
ively. When a dose increase was deemed necessary during study drug
administration, the dose could be increased up to the fourth dose
(hydromorphone 16mg/day, oxycodone 60mg/day) by one step every
24 h (Table 1). Treatment was switched to appropriate analgesics after
completion of study drug administration and after the post-study obser-
vation. The initial 4mg/day dosage of hydromorphone was set based
on 1–2mg per dose as specified by the World Health Organization.
The oxycodone hydrochloride powder dose used was that stipulated in
the Japanese package insert for opioid-naïve patients.
Every day, from baseline to treatment completion (or discontinu-
ation), patients evaluated their mean pain severity over the previous
24 h using the VAS and recorded their score in a diary. Oral mor-
phine hydrochloride solution was used as rescue medication for
both groups (Table 1). This is because, at the time of this study,
hydromorphone immediate-release tablets were not yet approved for
use in Japan, and so could not be used. If oxycodone hydrochloride
powder had been used as rescue medication, patients in the hydro-
morphone group might have used oxycodone, confounding the
evaluation of which drug was causing any AEs.
The following were prohibited throughout the study: coadministra-
tion of a monoamine oxidase inhibitor, opioid analgesic or narcotic
antagonist; new administration of systemic non-opioid analgesics; sup-
plementary analgesics; bisphosphonates; anti-RANKL antibody pre-
parations; changes in dosage and administration; new initiation of
radiotherapy, nerve block, percutaneous vertebroplasty, surgery, or
cancer chemotherapy or immunotherapy. Magnesium oxide at 2 g/day
and prochlorperazine maleate at 15mg/day were administered to all
patients to ensure adequate control of constipation and nausea/vomit-
ing and to enable appropriate safety evaluations.
Outcomes
The primary efficacy endpoint was the change in VAS, a 100-mm
rating scale commonly used in Japan to evaluate pain in clinical
studies of opioid analgesics, from baseline to treatment completion
or discontinuation. Mean pain over the previous 24 h was
Table 1. Daily dose of the investigational product and single dose







1 4mg/day 10mg/day 5 mg
2 8mg/day 20mg/day 5 mg
3 12mg/day 40mg/day 10mg
4 16mg/day 60mg/day 15mg
aAt the time of this study, hydromorphone immediate-release tablets were
not yet approved for use in Japan, so they could not be used. If oxycodone
hydrochloride powder had been used as rescue medication, patients in the
hydromorphone group might have used oxycodone, confounding the evalu-
ation of which drug was causing any AEs. Therefore, oral morphine solution
was chosen as the rescue medication for both groups.
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retrospectively evaluated by the participant on Days 1–6 as a sec-
ondary endpoint.
Changes in VAS and sleep, as an indicator of successful pain
relief, were also evaluated on each evaluation day (Days 1–6) as a
secondary endpoint. Sleep quality was evaluated at completion/dis-
continuation of treatment using a 4-point rating scale (0, very unsat-
isfactory or did not sleep at all; 1, markedly unsatisfactory; 2,
slightly unsatisfactory; and 3, satisfactory).
Safety endpoints were adverse events, laboratory data, vital signs
and 12-lead electrocardiogram (ECG).
Statistical analysis
The full analysis set (FAS) consisted of all patients with at least one
measurement of the primary efficacy parameter, at least one dose of
study medication, and no serious GCP violation, and was the pri-
mary analysis population for efficacy. The level of significance used
for the hypothesis test was 5% (two-sided), and the confidence inter-
val (CI) was 95% (two-sided). SAS System Release 9.2 (SAS Inc.,
Cary, NC, USA) was used for statistical analysis. Summary statistics
were calculated for VAS scores at baseline, at treatment completion/
discontinuation and for the change in VAS scores. For primary effi-
cacy evaluation, analysis of covariance (ANCOVA) was conducted
using the baseline VAS scores as a covariate to calculate the 95% CI
(two-sided) for a difference in the least squares mean in the magni-
tude of change in VAS scores between the hydromorphone and oxy-
codone groups. The numeric pain rating scale, a method widely
used in clinical settings, also employs an 11-step scale. Assuming
that the change between each step is equivalent to 10mm in the
VAS, the limit of non-inferiority was determined to be 10mm and
was considered a clinically acceptable difference against the oxy-
codone group. A sample size of 180 patients (N = 90/arm) was
determined to achieve a power of at least 80% to show non-
inferiority, assuming the difference in VAS change from baseline
between groups was 0mm and the standard deviation for this par-
ameter was 22.5mm, referring to other clinical studies in opioid-
naïve patients (data on file: available at http://www.pmda.go.jp/
drugs/2010/P201000027/index.html [in Japanese]). P values and
least squares means for each group were calculated.
Summary statistics were calculated for VAS scores on each evalu-
ation day (Days 1–6) and for changes in VAS scores between base-
line and each evaluation day. A t-test was conducted between
groups to calculate the 95% CI (two-sided) for a difference in
means. A paired t-test was conducted on baseline VAS scores and
VAS scores on each evaluation day (Days 2–6) to calculate the 95%
CI (two-sided) for a difference in means.
Results
Patients and treatment exposure
Figure 1 shows patient disposition. Of the 183 patients registered in
this study, 181 were randomized: 92 to the hydromorphone group
and 89 to the oxycodone group; of these, 85/92 and 75/89, respect-
ively, completed the study. The main reason for study discontinuation
was adverse events: 6/7 and 8/14 patients in the hydromorphone and
oxycodone groups, respectively.
A total of 172 patients were included in the FAS. Two patients
in the oxycodone group were excluded from the FAS because they
discontinued the study before initiation of the study drug.
Additionally, four patients in the hydromorphone group and three
in the oxycodone group were excluded because of other major
deviations. These patients were also excluded from the per-protocol
set (PPS) and safety analysis population. Protocol deviation was
observed in 10 and 18 patients in the hydromorphone and oxy-
codone groups, respectively; these patients were excluded from the
PPS.
Table 2 shows demographics of the FAS. Male patients
accounted for 61.4% (54/88) in the hydromorphone group, and
73.8% (62/84) in the oxycodone group. The proportion of patients
with ECOG PS of 0 was higher in the hydromorphone than oxy-
codone group (33.0% [29/88] vs 20.2% [17/84]). All other charac-
teristics were similar between the two groups.
Mean (standard deviation [SD]) baseline VAS scores in the FAS
were 54.8 (15.44) mm in the hydromorphone group and 53.9
(12.09) mm in the oxycodone group, with no notable difference
between groups.
Most patients in both groups, specifically 75.0% (66/88) in the
hydromorphone group and 71.4% (60/84) in the oxycodone group,
completed or discontinued without their dose being altered, with no
notable intergroup difference. A dose increase was required more
than twice for two patients in the hydromorphone group and six
patients in the oxycodone group.
There was no between-group difference in the use of rescue pain
medication: the mean daily use of such medication was less than
once for both groups on all evaluation days.
Efficacy
Table 3 shows the analysis of change in VAS scores for the FAS.
The mean (SD) VAS score was 54.8 (15.44) mm at baseline and
24.7 (22.11) mm at completion/discontinuation of treatment in the
hydromorphone group; corresponding values were 53.9 (12.09) mm
and 27.9 (21.05) mm in the oxycodone group, thus showing a
decrease from baseline in both groups.
The magnitude of change in mean VAS score [SD] from baseline
to completion/discontinuation of treatment was similar in the hydro-
morphone versus oxycodone group (−30.0 [24.12] vs −26.0 [3.65]
mm). The intergroup difference (95% CI) in the least squares mean
for change in VAS score at completion/discontinuation of treatment
was −3.4mm (−9.8 to 3.1mm) using ANCOVA. Given that the
upper limit of the 95% CI was <10mm—the non-inferiority limit
determined at the time of planning—non-inferiority of hydromor-
phone relative to oxycodone was suggested.
Figure 1. Patient disposition. FAS, full-analysis set.
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Figure 2 shows VAS scores on each evaluation day, a transition
diagram (mean ± SD) for measured VAS scores, and the magnitude
of change from baseline on each evaluation day. Mean VAS scores
decreased on Day 2 in both groups and the mean level of change
tended to increase with treatment progression. A paired t-test was
conducted for VAS scores at baseline and for each evaluation day
(Days 2–6). A significant difference was observed between baseline
VAS scores and those on each evaluation day (paired t-test: P <
0.0001). There was no significant intergroup difference at each
evaluation day.
Many patients in both groups showed improvements in sleep at
completion/discontinuation of treatment compared with baseline. A
significant difference was observed in both the hydromorphone
group (Wilcoxon signed rank test: P < 0.0001) and oxycodone
group (P = 0.0012); thus, there was no significant intergroup
difference.
Safety and tolerability
Table 4 shows adverse events that occurred with an incidence of
≥5%. Of the 181 randomized patients, 172 (88 in the hydromor-
phone group and 84 in the oxycodone group) were included in the
safety analysis, after excluding two patients (both in the oxycodone
group) who did not receive the study drug. Additionally, seven
patients (four in the hydromorphone group and three in the oxy-
codone group) were excluded for other major deviations. The inci-
dence of adverse events was 83.0% (73/88) in the hydromorphone
group and 77.4% (65/84) in the oxycodone group, and no signifi-
cant intergroup difference was observed. The most frequent adverse
events (incidence of ≥10%) were somnolence, constipation, vomit-
ing, nausea and diarrhea.
The incidence of serious adverse events (including death) was
8.0% (7/88) in the hydromorphone group and 9.5% (8/84) in the
oxycodone group, with no significant intergroup difference. Events
judged to be causally related to the study drug occurred in four
patients in the hydromorphone group (one event each of somno-
lence, aspiration pneumonia, toxic skin eruption and nausea/vomit-
ing), and three patients in the oxycodone group (one event each of
somnolence, aspiration pneumonia and abnormal hepatic function).
All patients improved or recovered after discontinuing the study
drug, or with appropriate medical intervention, except for the
patients with aspiration pneumonia and abnormal hepatic function,
both of whom died.
There were no pronounced changes in laboratory data or vital
signs. Clinically problematic QT prolongation was not observed
using 12-lead ECG.
Discussion
This was a double-blind, double-dummy comparative study to com-
pare the efficacy of hydromorphone immediate-release tablets with
Table 2. Baseline demographics and clinical characteristics
Hydromorphone
group N = 88
n (%)
Oxycodone
group N = 84
n (%)
Total N = 172
n (%)
Age (years)





Male 54 (61.4) 62 (73.8) 116 (67.4)
Female 34 (38.6) 22 (26.2) 56 (32.6)
Body weight (kg)




Body mass index (kg/m2)
<25 kg/m2 73 (83.0) 73 (86.9) 146 (84.9)
≥25 kg/m2 15 (17.0) 11 (13.1) 26 (15.1)
Underlying disease (tumor type)
Head/neck 2 (2.3) 0 (0.0) 2 (1.2)
Lung 30 (34.1) 33 (39.3) 63 (36.6)
Breast 4 (4.5) 0 (0.0) 4 (2.3)
Gastrointestinal 24 (27.3) 26 (31.0) 50 (29.1)
Hepatic-biliary-
pancreatic
13 (14.8) 9 (10.7) 22 (12.8)
Urogenital 11 (12.5) 9 (10.7) 20 (11.6)
Others 4 (4.5) 7 (8.3) 11 (6.4)
ECOG performance status
0 29 (33.0) 17 (20.2) 46 (26.7)
1 38 (43.2) 41 (48.8) 79 (45.9)
2 16 (18.2) 17 (20.2) 33 (19.2)
3 5 (5.7) 9 (10.7) 14 (8.1)
4 0 (0.0) 0 (0.0) 0 (0.0)
VAS (mm)




VAS, visual analog scale; ECOG, Eastern Cooperative Oncology Group.
Table 3. Changes in visual analog scale scores in the full-analysis
set
Hydromorphone









VAS (at completion/discontinuation of treatment; mm)
Mean 24.7 27.9




VAS (change from baseline to completion/discontinuation of treatment;
mm)
Mean −30.0 −26.0




Least squares meana −29.7 −26.4
Difference in least squares
meana
−3.4




Analysis of covariance (explanatory variable: baseline VAS, groups).
ahydromorphone group − oxycodone group.
VAS, visual analog scale.
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oxycodone hydrochloride immediate-release powder. The results
showed equivalent efficacy and safety between treatments. Our data
demonstrate that hydromorphone immediate-release tablets can
achieve clinically meaningful pain management in Japanese patients
with cancer. Only opioid-naïve cancer patients were included to
eliminate potential bias from previous opioid analgesia.
The dosing interval of hydromorphone immediate-release tablets
is reported to be ~4 h (1,10–14), but in this double-dummy study,
hydromorphone had to be administered four times daily to match
the administration of oxycodone.
There was a significant improvement in sleep scores compared
with baseline in both treatment groups, with no significant inter-
group difference. The type and incidence of adverse events did not
differ greatly from previous reports (15–19).
The results of this study suggest that the analgesic effect of hydro-
morphone immediate-release tablets given four times daily was compar-
able with that of oxycodone immediate-release powder, even though,
typically, the standard regimen of hydromorphone is administered every
4 h (equivalent to six doses daily). With the latter schedule, or with
administration of immediate-release morphine formulations, patients
must be woken for drug administration at 4-hourly intervals; patients
are therefore not permitted to sleep continuously for more than 4 h. As
four-times-daily hydromorphone proved non-inferior to oxycodone in
the present analysis, this hydromorphone schedule may have quality-of-
life advantages over conventional opioid regimens. That is, the need to
interrupt night-time sleep to administer conventional opioid medication
can be avoided, as can double-dosing before bedtime and the potential
for overdose-related adverse events during sleep. Because of these poten-
tial benefits, four-times-daily hydromorphone may be an appropriate
treatment schedule for opioid-naïve patients.
Our study had some limitations. The analgesic effect was investi-
gated only at relatively low doses because patients were opioid-naïve,
so the efficacy and safety of four daily doses of hydromorphone need
to be confirmed in patients who switch from other opioids, and in
patients who require high-dose opioids. All patients in this study were
required to take a laxative and antiemetics so that it was possible to
compare between groups the onset of nausea/vomiting and constipa-
tion, which are adverse drug reactions often observed with opioids
(20). The impact of prophylactic administration of laxatives and
antiemetics on opioid safety has not been specifically investigated,
and the incidence and severity of nausea/vomiting and constipation
observed in this study cannot be compared with other studies that did
not include prophylactic antiemetics and laxatives.
Conclusions
We verified the non-inferiority of hydromorphone given four times
daily relative to oxycodone given four times daily in Japanese opi-
oid-naïve cancer patients. There were no notable intergroup differ-
ences in the incidence of adverse events or serious adverse events.
The efficacy and safety of hydromorphone tablets are, therefore,
comparable to those of oxycodone immediate-release powder.
Figure 2. Changes in visual analog scale scores in the full-analysis set.
Table 4. List of adverse events with incidence of ≥5%
PTa Hydromorphone











73 (83.0) 65 (77.4) 138 (80.2)
Somnolence 23 (26.1) 21 (25.0) 44 (25.6)
Constipation 21 (23.9) 19 (22.6) 40 (23.3)
Vomiting 17 (19.3) 15 (17.9) 32 (18.6)
Nausea 14 (15.9) 14 (16.7) 28 (16.3)
Diarrhea 12 (13.6) 9 (10.7) 21 (12.2)
Delirium 2 (2.3) 5 (6.0) 7 (4.1)
aMedDRA V.16.1 Preferred Term (PT).
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Supplementary data are available at Japanese Journal of Clinical
Oncology online.
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